secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2026-09-10T20:05:37+00:00
Accession:  0001819790-26-000066
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus closes $270M cash + stock buy of Alkeus; adds Stargardt drug ALK-001
---------------------------------------------------------------------------

- Up-front consideration: $270M cash plus 2,908,692 Tarsus shares to Alkeus equityholders.
- Milestones up to $350M: $250M on US regulatory approval, $100M on first US sale; plus low-to-mid single-digit revenue share.
- Adds ALK-001, Phase 3 oral for Stargardt disease, with FDA Breakthrough, Orphan, Fast Track, Rare Pediatric designations.
- NORTHSTAR Phase 3 trial ongoing; topline data expected 2029.
- Acquisition closed Sept 4, 2026; Alkeus becomes wholly-owned subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000066/0001819790-26-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000066/tars-20260904.htm
  HTML page:      https://secwatch.observer/filing/0001819790-26-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer